Human ErbB4 / Her4 Protein, His Tag
分子別名(Synonym)
HER4,ErbB4,MGC138404,p180erbB4
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human ErbB4, His Tag (ER4-H5221) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Pro 651 (Accession # NP_005226.1).
Predicted N-terminus: Gln 26
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 70.7 kDa. The protein migrates as 95-110 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
受體酪氨酸蛋白激酶erbB-4(ErbB4),也稱為Her4,是一種單程I型跨膜糖蛋白,是酪氨酸激酶受體erbB家族的成員。ErbB家族成員是表皮生長(zhǎng)因子(EGF)家族生長(zhǎng)因子的受體。ErbB4在正常骨骼肌、心臟、垂體、腦和幾種乳腺癌中表達(dá)。ERBB4包含多個(gè)富含半胱氨酸的弗林蛋白酶樣結(jié)構(gòu)域、一個(gè)酪氨酸激酶結(jié)構(gòu)域、磷酸肌醇-3激酶結(jié)合位點(diǎn)和一個(gè)PDZ結(jié)構(gòu)域結(jié)合基序。該蛋白與神經(jīng)調(diào)節(jié)蛋白-2和-3、肝素結(jié)合EGF樣生長(zhǎng)因子和β細(xì)胞蛋白結(jié)合并被其激活。配體結(jié)合誘導(dǎo)多種細(xì)胞反應(yīng),包括有絲分裂和分化。多種蛋白水解事件允許釋放細(xì)胞質(zhì)片段和細(xì)胞外片段。ErbB4在神經(jīng)元發(fā)育、心臟發(fā)育和癌癥中起著重要作用。ERBB4已被證明與DLG4、NRG1、STAT5A和YAP1相互作用。該基因的突變與癌癥有關(guān)。其他單核苷酸多態(tài)性和風(fēng)險(xiǎn)單倍型與精神分裂癥有關(guān)。
關(guān)鍵字: ErbB4;ErbB4蛋白;ErbB4重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。